Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic targeting of cathepsin C: from pathophysiology to treatment.
Korkmaz B, Caughey GH, Chapple I, Gauthier F, Hirschfeld J, Jenne DE, Kettritz R, Lalmanach G, Lamort AS, Lauritzen C, Łȩgowska M, Lesner A, Marchand-Adam S, McKaig SJ, Moss C, Pedersen J, Roberts H, Schreiber A, Seren S, Thakker NS. Korkmaz B, et al. Among authors: lamort as. Pharmacol Ther. 2018 Oct;190:202-236. doi: 10.1016/j.pharmthera.2018.05.011. Epub 2018 May 26. Pharmacol Ther. 2018. PMID: 29842917 Review.
Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases.
Guarino C, Hamon Y, Croix C, Lamort AS, Dallet-Choisy S, Marchand-Adam S, Lesner A, Baranek T, Viaud-Massuard MC, Lauritzen C, Pedersen J, Heuzé-Vourc'h N, Si-Tahar M, Fıratlı E, Jenne DE, Gauthier F, Horwitz MS, Borregaard N, Korkmaz B. Guarino C, et al. Among authors: lamort as. Biochem Pharmacol. 2017 May 1;131:52-67. doi: 10.1016/j.bcp.2017.02.009. Epub 2017 Feb 11. Biochem Pharmacol. 2017. PMID: 28193451
Cathepsin C inhibition as a potential treatment strategy in cancer.
Korkmaz B, Lamort AS, Domain R, Beauvillain C, Gieldon A, Yildirim AÖ, Stathopoulos GT, Rhimi M, Jenne DE, Kettritz R. Korkmaz B, et al. Among authors: lamort as. Biochem Pharmacol. 2021 Dec;194:114803. doi: 10.1016/j.bcp.2021.114803. Epub 2021 Oct 20. Biochem Pharmacol. 2021. PMID: 34678221 Review.
Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors.
Klotz LV, Courty Y, Lindner M, Petit-Courty A, Stowasser A, Koch I, Eichhorn ME, Lilis I, Morresi-Hauf A, Arendt KAM, Pepe M, Giopanou I, Ntaliarda G, Behrend SJ, Oplopoiou M, Gissot V, Guyetant S, Marchand-Adam S, Behr J, Kaiser JC, Hatz RA, Lamort AS, Stathopoulos GT. Klotz LV, et al. Among authors: lamort as. Cancer Med. 2019 Apr;8(4):1486-1499. doi: 10.1002/cam4.2031. Epub 2019 Feb 25. Cancer Med. 2019. PMID: 30806043 Free PMC article.
Tobacco chemical-induced mouse lung adenocarcinoma cell lines pin the prolactin orthologue proliferin as a lung tumour promoter.
Kanellakis NI, Giannou AD, Pepe MAA, Agalioti T, Zazara DE, Giopanou I, Psallidas I, Spella M, Marazioti A, Arendt KAM, Lamort AS, Champeris Tsaniras S, Taraviras S, Papadaki H, Lilis I, Stathopoulos GT. Kanellakis NI, et al. Among authors: lamort as. Carcinogenesis. 2019 Nov 25;40(11):1352-1362. doi: 10.1093/carcin/bgz047. Carcinogenesis. 2019. PMID: 30828726
Osteopontin drives KRAS-mutant lung adenocarcinoma.
Giopanou I, Kanellakis NI, Giannou AD, Lilis I, Marazioti A, Spella M, Papaleonidopoulos V, Simoes DCM, Zazara DE, Agalioti T, Moschos C, Magkouta S, Kalomenidis I, Panoutsakopoulou V, Lamort AS, Stathopoulos GT, Psallidas I. Giopanou I, et al. Among authors: lamort as. Carcinogenesis. 2020 Aug 12;41(8):1134-1144. doi: 10.1093/carcin/bgz190. Carcinogenesis. 2020. PMID: 31740923
An In Vivo Inflammatory Loop Potentiates KRAS Blockade.
Arendt KAM, Ntaliarda G, Armenis V, Kati D, Henning C, Giotopoulou GA, Pepe MAA, Klotz LV, Lamort AS, Hatz RA, Kobold S, Schamberger AC, Stathopoulos GT. Arendt KAM, et al. Among authors: lamort as. Biomedicines. 2022 Mar 3;10(3):592. doi: 10.3390/biomedicines10030592. Biomedicines. 2022. PMID: 35327394 Free PMC article.
17 results